Novo Nordisk (NVO) Q1 2026 Earnings Boosted by Wegovy Demand

AI Summary

Novo Nordisk (NVO) reported first-quarter revenue of 96.82 billion kroner, a 24% increase year-over-year, largely driven by sales of its Wegovy weight loss pill, which generated 2.26 billion kroner ($353.6 million) from 1.3 million prescriptions. The drugmaker has raised its full-year guidance, now projecting adjusted sales and operating profit to decline between 4% and 12% in constant-currency terms, improving from prior estimates. The CEO noted that Wegovy captures 65% of new U.S. prescriptions in its category. Despite prior challenges, the earnings report indicates a recovery and better growth prospects ahead.